Selumetinib
Spezifikationen
606143-52-6CAS-Nummer
641-434-6EG-Nummer
6-(4-bromo-2-chloroanilino)-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamideIUPAC-Name
C17H15BrClFN4O3Chemische Formel
457.7 g/molMolekulargewicht
Selumetinib; 606143-52-6; AZD6244; ARRY-142886; 5-[(4-BROMO-2-CHLOROPHENYL)AMINO]-4-FLUORO-N-(2-HYDROXYETHOXY)-1-METHYL-1H-BENZIMIDAZOLE-6-CARBOXAMIDE; AZD 6244; AZD-6244; ARRY-886; selumetinibum; DTXSID3048944; 6UH91I579U; ARRY142886; DTXCID0028870; CHEBI:90227; 1H-Benzimidazole-6-carboxamide, 5-((4-bromo-2-chlorophenyl)amino)-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-; 1H-Benzimidazole-6-carboxamide, 5-[(4-bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-; 5-((4-BROMO-2-CHLOROPHENYL)AMINO)-4-FLUORO-N-(2-HYDROXYETHOXY)-1-METHYL-1H-BENZIMIDAZOLE-6-CARBOXAMIDE; RefChem:58514; MEK inhibitor AZD6244; Selumetinib (AZD6244); ARRY 142886; AZD6244 (Selumetinib); 5-((4-bromo-2-chlorophenyl)amino)-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzo[d]imidazole-6-carboxamide; MFCD11977472; C17H15BrClFN4O3; Selumetinib [USAN:INN]; Koselugo; UNII-6UH91I579U; CHEMBL1614701; NSC741078; s1008; 6-(4-bromo-2-chloroanilino)-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide; NCGC00189073-01; NCGC00189073-02; 6-(4-bromo-2-chloro-anilino)-7-fluoro-N-(2-hydroxyethoxy)-3-methyl-benzimidazole-5-carboxamide; 5-[(4-bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-1,3-benzodiazole-6-carboxamide; AZD 6244;5-((4-Bromo-2-chlorophenyl)amino)-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzo[d]imidazole-6-carboxamide;6-(4-bromo-2-chlorophenylamino)-7-fluoro-N-(2-hydroxyethoxy)-3-methyl-3H-benzo[d]imidazole-5-carboxamide; CAS-606143-52-6; 5-(4-broMo-2-chlorophenylaMino)-4-fluoro-N-(2-hydroxyethoxy)-1-Methyl-1H-benzo[d]iMidazole-6-carboxaMide; 3EW; SELUMETINIB [MI]; SELUMETINIB [INN]; Selumetinib (USAN/INN); Array142886; SELUMETINIB [USAN]; SELUMETINIB [WHO-DD]; SCHEMBL155456; GTPL5665; orb1224491; orb1300969; SCHEMBL29353582; SCHEMBL29555068; EX-A020; CYOHGALHFOKKQC-UHFFFAOYSA-N; GLXC-90014; HMS3244G03; HMS3244G04; HMS3244H03; HMS3265K01; HMS3265K02; HMS3265L01; HMS3265L02; HMS3654O03; HMS5079E03; NSC 741O78; Tox21_113362; BDBM50355497; EBC-11361; NSC800882; s1846; AKOS015904255; Tox21_113362_1; CCG-264774; CS-0059; DB11689; EX-8621; FS27812; NSC-741078; NSC-800882; SB14707; SDCCGSBI-0654324.P001; SelumetinibAZD6244, ARRY-142886; NCGC00189073-05; NCGC00189073-07; 6-(4-bromo-2-chlorophenylamino)-7-fluoro-N-(2-hydroxyethoxy)-3-methyl-3H-benzo[d]imidazole-5-carboxamide; 6-[(4-bromo-2-chlorophenyl)amino]-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide; AC-25059; AZD6244,Selumetinib, ARRY-142886; HY-50706; Selumetinib (ARRY142886/AZD6244); SY013317; AZD6244 (Selumetinib,ARRY-142886)?; NS00071922; SW202561-3; T6218; D09666; EN300-18166787; F361876; Q7448840; BRD-K57080016-001-01-9; BRD-K57080016-001-15-9; BRD-K57080016-001-19-1; 1H-BENZIMIDAZOLE-6-CARBOXAMIDE, 5-((4-BROMO-2-CHLOROPHENYL)AMINO)-4-FLUORO-N-(2- HYDROXYETHOXY)-1-METHYL-; 5-(4-Bromo-2-chloroanilino)-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-1,3-benzimidazole-6-carboxamide; 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy -ethoxy)-amide; 6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide; 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid(2-hydroxy-ethoxy)-amide; 6-(4-bromo-2-chlorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethoxy)-amide; 6-(4-bromo-2-chlorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid(2-hydroxyethoxy)-amide; 6-(4-bromo-2chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amideSynonyme
